Brief: Olipass Corp SCN9A Antisense Pain Killer OLP-1002 Moves Into Phase 2A Stage
25/10/2021 13:40
Oct 25 (Reuters) - OliPass Corp 244460.KQ :
* OLIPASS CORP - SCN9A ANTISENSE PAIN KILLER OLP-1002 MOVES
INTO
PHASE 2A STAGE
* OLIPASS CORP - TO INITIATE A PHASE 2A TRIAL FOR SCN9A
ANTISENSE
PAIN KILLER OLP-1002 IN AUSTRALIA
* OLIPASS CORP - PLANNING ADDITIONAL PHASE 2A TRIAL IN US
FOR
CHEMOTHERAPY-INDUCED NEUROPATHIC PAIN (CINP)
Source text for Eikon: ID:nPnrF6fda
Further company coverage: 244460.KQ
Recent news on OliPass
See all newsBrief: Olipass To Acquire Real Estate Worth 72 Billion Won
Brief: Olipass To Conduct Capital Increase Of 6.5 Billion Won
Brief: Olipass To Conduct Capital Increase Of 5 Billion Won For Operational Funds
Brief: Vanda Pharmaceuticals And OliPass Announce Strategic Partnership To Develop Antisense Oligonucleotide Therapeutics
Brief: Olipass Corp SCN9A Antisense Pain Killer OLP-1002 Moves Into Phase 2A Stage